Hammer Labz Fury Caps: Capsule Pre-Workout Label Analysis

A label analysis of Hammer Labz Fury Caps: caffeine, DMHA, Eria jarensis, two forms of yohimbine and phenibut in two capsules, with the evidence behind each ingredient and its legal and anti-doping status.

Fury Caps at a glance

Fury Caps is a high-stimulant pre-workout in capsules from the Hammer Labz Black Series. Two capsules carry caffeine, DMHA, Eria jarensis, two forms of yohimbine and phenibut, with 30 servings per tub. It suits experienced lifters who know their stimulant tolerance and would rather swallow two capsules than mix a powder.

  • Formula: caffeine, the base of the formula, has strong human evidence; yohimbine has a few small trials, and DMHA, Eria jarensis and alpha-yohimbine have none in people.
  • Dosing: every ingredient is listed with its amount, with no proprietary blend. Not scored, because we do not rate amounts of phenibut or DMHA.
  • Effect: not rated: label analysis.
  • Value: not rated.

Updated 19 November 2026.

This is a label analysis. We have not used Fury Caps for this review; the formula comes from the supplement facts panel published for the product in November 2026. More on our method: how we review.

Which version of Fury Caps is this

This review covers Hammer Labz Fury Caps in the 60-capsule tub with the Black Series label. The panel gives a serving of two capsules and 30 servings per container. It does not say which market the product is made for, so we cannot tell whether a US and an EU version of Fury Caps differ.

What’s in Fury Caps

Ingredient (label spelling)Per 2 capsulesEvidence
Caffeine anhydrous250 mgHuman trials
Phenibut300 mgNot assessed (see below)
DMHA150 mgAnimal studies
Eria jarensis100 mgNone
Dicaffeine malate (Infinergy™)50 mgNone
Yohimbine HCl5 mgHuman trials
Alpha yohimbine4 mgAnimal studies

Seven ingredients, all with their amounts. The formula has no pump or amino acid side: everything in it either stimulates or, in the case of phenibut, acts on the nervous system in a different way.

How the Fury Caps formula works

The label splits into three parts: a caffeine-led stim formula, yohimbine in two forms, and phenibut, which has its own section below.

The stim formula: caffeine, DMHA and Eria jarensis

Caffeine is the base: 250 mg of caffeine anhydrous, plus 50 mg of dicaffeine malate. It is the best-researched ingredient in the formula. The International Society of Sports Nutrition position stand found that caffeine improves performance in many, though not all, studies. The gains are small to moderate and cover muscular endurance, movement velocity, strength, sprinting and jumping. The same stand notes that pre-workout supplements containing caffeine have improved both anaerobic and aerobic performance.

Dicaffeine malate is caffeine bound to malic acid, sold under the Infinergy name. We found no published study of the compound itself in PubMed (search of 19 November 2026).

DMHA (150 mg) is the only name the label gives for this ingredient. The name is used for two related compounds: octodrine (2-amino-6-methylheptane, also written 1,5-dimethylhexylamine) and 2-amino-5-methylheptane. A 2018 review describes octodrine as a central nervous system stimulant, first developed as a nasal decongestant, that returned to the market in pre-workouts and fat burners. The pharmacology papers on it are animal studies from the 1940s to the 1970s; we found no controlled trial of DMHA in people. The same review found only five relevant publications and listed side effects reported online, mostly on forums: high blood pressure, shortness of breath and overheating.

Eria jarensis (100 mg) is an orchid promoted as a source of N,N-dimethylphenethylamine. The only study of it we found in PubMed (search of 19 November 2026) is a 2025 laboratory analysis of 12 US supplements sold as containing Eria jarensis. None matched its label, and four contained a stimulant that the label did not list. The abstract does not name the products, so we cannot say whether Fury Caps was among them. There are no trials of the extract in people.

Yohimbine in two forms

Fury Caps lists 5 mg of yohimbine HCl and 4 mg of alpha-yohimbine, also called rauwolscine. Yohimbine blocks alpha-2 adrenergic receptors, which act as a brake on fat release from fat cells. In healthy male volunteers, oral yohimbine raised blood noradrenaline by 40 to 50% and mobilised fat; the effect was stronger during exercise and disappeared after a meal.

The training evidence comes from a few small trials. In a 21-day randomised trial in 20 professional male soccer players, body fat in the yohimbine group fell from 9.3% to 7.1%. Body mass, muscle mass and performance tests did not change in either group. In a crossover trial in 18 physically active women, a single serving of yohimbine HCl raised mean power and total work across three 15-second cycle sprints, compared with placebo. Alpha-yohimbine is used mainly as a laboratory tool for studying alpha-2 receptors; we found no controlled trial of it as a supplement in people. More on both forms in our yohimbine card.

Phenibut in a pre-workout

Phenibut is a derivative of GABA, the brain’s main inhibitory neurotransmitter. It was developed as a medicine in the former Soviet Union. In the EU it is the active substance of one authorised medicine, Noofen, in Latvia. Fury Caps lists 300 mg per two capsules.

Published case reports describe intoxication, dependence and withdrawal linked to phenibut. In a systematic review of 62 published cases of phenibut toxicity and withdrawal, 63% also involved other substances, most often benzodiazepines and alcohol. Check with a doctor before using a product that contains phenibut, and do not combine it with alcohol, sedatives or other medicines that act on the nervous system.

Who Fury Caps is for

Fury Caps is for experienced lifters who already know how they react to strong stimulants and want a capsule instead of a powder. It suits hard sessions where stimulation matters more than a pump. If you want citrulline and a pump formula in the same product, the Hammer Labz range has powder and liquid options. One serving lists 250 mg of caffeine plus dicaffeine malate. EFSA considers single doses of caffeine up to 200 mg, and up to 400 mg a day from all sources, of no safety concern for healthy adults other than pregnant women. Count the caffeine from coffee and other products on training days. Check with a doctor first if you have high blood pressure, a heart condition or take any medication.

Legal and anti-doping status

Status checked on 19 November 2026.

  • DMHA: octodrine, one of two compounds sold as DMHA, is named by WADA in class S6 (stimulants), prohibited in competition; class S6 also covers stimulants it does not name. The label does not give a chemical name. Octodrine appears neither in the European Medicines Agency’s database of medicines authorised in the EU and EEA nor in the EU novel food catalogue. More on DMHA: our DMHA card.
  • Eria jarensis: not named on the 2026 or 2027 WADA List. Class S6 prohibits all stimulants in competition, including those it does not name; whether this extract is covered is for an anti-doping organisation to decide. Not in the EU novel food catalogue.
  • Yohimbine and alpha-yohimbine: the EU prohibits yohimbe bark and its preparations in foods, and yohimbine hydrochloride is the active substance of medicines authorised in five EU countries. The MHRA has said that products containing yohimbine would normally be controlled as prescription-only medicines in the UK. Neither compound is named on the 2026 or 2027 WADA List.
  • Phenibut: the EMA database lists one phenibut medicine, Noofen, authorised in Latvia, and none in other EU countries. Not in the EU novel food catalogue and not named on the 2026 or 2027 WADA List. In the UK, phenibut was among the products the MHRA seized in a 2014 action against unlicensed “smart drugs”.
  • Caffeine: on WADA’s Monitoring Program, not on the Prohibited List.

Not for drug-tested athletes: DMHA is prohibited in competition. Status differs by country and changes over time, so check the rules where you live.

This review replaces an earlier version of this article, which made claims about phenibut and other ingredients that our sources do not support.

Sources

  1. Product label: Hammer Labz Fury Caps, 60 capsules, supplement facts panel and front label (Black Series), as published for the product in November 2026. Read on 19 November 2026.
  2. Guest NS, VanDusseldorp TA, Nelson MT, et al. (2021). International society of sports nutrition position stand: caffeine and exercise performance. J Int Soc Sports Nutr, 18(1), 1. PMID: 33388079.
  3. Catalani V, Prilutskaya M, Al-Imam A, et al. (2018). Octodrine: New Questions and Challenges in Sport Supplements. Brain Sci, 8(2), 34. PMID: 29461475.
  4. Cohen PA, Abarca R, Sovereign A, et al. (2025). Presence and quantity of ingredients in sports supplements purportedly containing the orchid Eria jarensis. Clin Toxicol (Phila), 63(11), 993–997. PMID: 40679500.
  5. Galitzky J, Taouis M, Berlan M, et al. (1988). Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest, 18(6), 587–594. PMID: 2906290.
  6. Ostojic SM (2006). Yohimbine: the effects on body composition and exercise performance in soccer players. Res Sports Med, 14(4), 289–299. PMID: 17214405.
  7. Barnes ME, Cowan CR, Boag LE, et al. (2022). Effects of Acute Yohimbine Hydrochloride Supplementation on Repeated Supramaximal Sprint Performance. Int J Environ Res Public Health, 19(3), 1316. PMID: 35162339.
  8. Halme M, Sjöholm B, Savola JM, et al. (1995). Recombinant human alpha 2-adrenoceptor subtypes: comparison of [3H]rauwolscine, [3H]atipamezole and [3H]RX821002 as radioligands. Biochim Biophys Acta, 1266(2), 207–214. PMID: 7742388.
  9. Gurley BJ, Koturbash I (2024). Phenibut: A drug with one too many “buts”. Basic Clin Pharmacol Toxicol, 135(4), 409–416. PMID: 39197876.
  10. Weleff J, Kovacevich A, Burson J, et al. (2023). Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review. J Addict Med, 17(4), 407–417. PMID: 37579098.
  11. European Food Safety Authority. Caffeine. Topic page summarising the 2015 Scientific Opinion on the safety of caffeine (EFSA Journal, 13(5), 4102). Accessed 19 November 2026.
  12. European Medicines Agency. Article 57 product data: medicines authorised in the EU and EEA. Data file updated 12 November 2026. Accessed 19 November 2026.
  13. European Commission. EU Novel Food status catalogue. Accessed 19 November 2026.
  14. European Union. Regulation (EC) No 1925/2006, Annex III: substances whose use in foods is prohibited, restricted or under scrutiny. Consolidated text of 15 May 2019. Accessed 19 November 2026.
  15. Medicines and Healthcare products Regulatory Agency (2021). Freedom of Information responses from the MHRA, week commencing 2 August 2021 (FOI 21/779: yohimbine, synephrine and ephedrine). Accessed 19 November 2026.
  16. Medicines and Healthcare products Regulatory Agency (2014). Medicines watchdog makes record seizure of experimental smart drugs. Press release, 24 October 2014. Accessed 19 November 2026.
  17. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force from 1 January 2026. Accessed 19 November 2026.
  18. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. In force from 1 January 2027. Accessed 19 November 2026.